Immunovia’s Presentation of Q1 Interim Report 2023, on May 23, 2023
Immunovia AB published the company’s Q2 Interim Report 2023 on Wednesday, August 30, 2023, at 8:30 am CET.
Place: Immunovia website
Listen to Immunovia’s conference call related to the planned changes announced on July 11, 2023
IMMray™ PanCan-d is provided as a laboratory developed test (LDT) exclusively by Immunovia, Inc. in the US.
The Immunovia AB share is, since 3 April 2018, traded on Nasdaq Stockholm. Immunovia has one class of shares. The Company has a registered share capital of SEK 1,131,579.05 allocated among 22,631,581 shares. The par value of the shares is SEK 0.05 per share.
Ticker on Nasdaq Stockholm: IMMNOV
The shares are registered by Euroclear Sweden.
If you have further questions, please contact our IR contact.
If you are interested in receiving our press releases and reports, please click on “Subscribe”.